{"id":311279,"date":"2025-08-02T06:52:20","date_gmt":"2025-08-02T06:52:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/311279\/"},"modified":"2025-08-02T06:52:20","modified_gmt":"2025-08-02T06:52:20","slug":"bridging-psychiatry-and-rare-genetic-diseases-a-scoping-review-of-therapeutic-strategies-and-diagnostic-delay-paired-with-healthcare-economic-burden-analysis-orphanet-journal-of-rare-diseases","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/311279\/","title":{"rendered":"Bridging psychiatry and rare genetic diseases: a scoping review of therapeutic strategies and diagnostic delay paired with healthcare economic burden analysis | Orphanet Journal of Rare Diseases"},"content":{"rendered":"
  • \n

    Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Benito-Lozano J, L\u00f3pez-Villalba B, Arias-Merino G, De la PosadaPaz M, Alonso-Ferreira V. Diagnostic delay in rare diseases: data from the Spanish rare diseases patient registry. Orphanet J Rare Dis. 2022;17(1):418.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Michaels-Igbokwe C, McInnes B, MacDonald KV, Currie GR, Omar F, Shewchuk B, Bernier FP, Marshall DA. (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta. Canada Genet Med. 2021;23(2):272\u20139.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Siegel IJ, Vaithilingam SL, Hartig MM, Patty EC, Mantsch LE, Garrison SR. Diagnostic delays in rare genetic disorders with neuropsychiatric manifestations: a systematic review. Eur J Med Genet. 2025;75: 105016.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tinker RJ, Fisher M, Gimeno AF, Gill K, Ivey C, Peterson JF, Bastarache L. Diagnostic delay in monogenic disease: a scoping review. Genet Med. 2024;26(4): 101074.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, Elliott EJ, Group ARDIoFS. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12(1): 68.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, Nowak D, Hasche C, Chan CH, Griese E, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1): 429.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Garrison SR, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions. Health Affairs 2022.<\/p>\n<\/li>\n

  • \n

    Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med. 2021;23(11):2194\u2013201.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bonnot O, Klunemann HH, Velten C, Torres Martin JV, Walterfang M. Systematic review of psychiatric signs in Niemann-Pick disease type C. World J Biol Psychiatry. 2019;20(4):320\u201332.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, Levy Y, Glazer D, Wilson J, Lawler M, et al. Integrating genomics into healthcare: a global responsibility. Am J Hum Genet. 2019;104(1):13\u201320.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Baum ML, Widge AS, Carpenter LL, McDonald WM, Cohen BM, Nemeroff CB, American Psychiatric Association Workgroup on B, Novel T. Pharmacogenomic clinical support tools for the treatment of depression. Am J Psychiatry. 2024;181(7):591\u2013607.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Food, Administration D. FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. http:\/\/wwwfdagov\/bbs\/topics\/news\/2004\/NEW01124html 2004.<\/p>\n<\/li>\n

  • \n

    Dyar B, Meaddough E, Sarasua SM, Rogers C, Phelan K, Boccuto L. Genetic findings as the potential basis of personalized pharmacotherapy in Phelan-McDermid syndrome. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12081192<\/a>.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Srivastava S, Sahin M, Buxbaum JD, Berry-Kravis E, Soorya LV, Thurm A, Bernstein JA, Asante-Otoo A, Bennett WE Jr, Betancur C, et al. Updated consensus guidelines on the management of Phelan-McDermid syndrome. Am J Med Genet A. 2023;191(8):2015\u201344.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Uhlenbusch N, Swaydan J, Holler A, Lowe B, Depping MK. Affective and anxiety disorders in patients with different rare chronic diseases: a systematic review and meta-analysis. Psychol Med. 2021. https:\/\/doi.org\/10.1017\/S0033291721003792<\/a>.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Orphanet. Free datasets powered by Orphanet. In.;2022.<\/p>\n<\/li>\n

  • \n

    McKusick VA. Mendelian inheritance in Man and its online version, OMIM. Am J Hum Genet. 2007;80(4):588\u2013604.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    HCUP National Inpatient Sample (NIS). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019<\/p>\n<\/li>\n

  • \n

    HCUP Kids\u2019 Inpatient Database (KID). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.<\/p>\n<\/li>\n

  • \n

    HCUP National Readmissions Database (NRD). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.<\/p>\n<\/li>\n

  • \n

    HCUP Nationwide Emergency Department Sample (NEDS). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.<\/p>\n<\/li>\n

  • \n

    Wu AC, McMahon P, Lu C. Ending the diagnostic odyssey-is whole-genome sequencing the answer? JAMA Pediatr. 2020;174(9):821\u20132.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    de Vasconcelos P, Lacerda JF. Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism. Front Cell Neurosci. 2022;16: 895511.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kartha RV, Zhou J, Basso L, Schroder H, Orchard PJ, Cloyd J. Mechanisms of antioxidant induction with high-dose N-acetylcysteine in childhood cerebral adrenoleukodystrophy. CNS Drugs. 2015;29(12):1041\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, Ciotti F, Sarzana M, Fraschini M, Zambon AA, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399(10322):372\u201383.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Costei C, Barbarosie M, Bernard G, Brais B, La Piana R. Adult hereditary white matter diseases with psychiatric presentation: clinical pointers and MRI algorithm to guide the diagnostic process. J Neuropsychiatry Clin Neurosci. 2021;33(3):180\u201393.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rosebush PI, Garside S, Levinson AJ, Mazurek MF. The neuropsychiatry of adult-onset adrenoleukodystrophy. J Neuropsychiatry Clin Neurosci. 1999;11(3):315\u201327.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    van Geel BM, Assies J, Wanders RJ, Barth PG. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997;63(1):4\u201314.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14(1):89.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol. 1992;49(4):401\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Shaimardanova AA, Chulpanova DS, Solovyeva VV, Mullagulova AI, Kitaeva KV, Allegrucci C, Rizvanov AA. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne). 2020;7: 576221.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013;3(9): e302.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wong JC, Walsh K, Hayden D, Eichler FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647\u201356.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bassuk AG, Joshi A, Burton BK, Larsen MB, Burrowes DM, Stack C. Alexander disease with serial MRS and a new mutation in the glial fibrillary acidic protein gene. Neurology. 2003;61(7):1014\u20135.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Prust M, Wang J, Morizono H, Messing A, Brenner M, Gordon E, Hartka T, Sokohl A, Schiffmann R, Gordish-Dressman H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011;77(13):1287\u201394.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134(3):351\u201382.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tsuyusaki Y, Shimbo H, Wada T, Iai M, Tsuji M, Yamashita S, Aida N, Kure S, Osaka H. Paradoxical increase in seizure frequency with valproate in nonketotic hyperglycinemia. Brain Dev. 2012;34(1):72\u20135.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Subramanian V, Kadiyala P, Hariharan P, Neeraj E. A rare case of glycine encephalopathy unveiled by valproate therapy. J Pediatr Neurosci. 2015;10(2):143\u20135.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Walterfang M, Fietz M, Fahey M, Sullivan D, Leane P, Lubman DI, Velakoulis D. The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci. 2006;18(2):158\u201370.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Golechha GR, Chatterjee SB, Sethi BB, Agarwal SS. Acute porphyria amongst psychiatric patients. Indian J Psychiatry. 1981;23(4):365\u20139.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161\u201378.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rinaldi B, Villa R, Sironi A, Garavelli L, Finelli P, Bedeschi MF. Smith-Magenis syndrome-clinical review, biological background and related disorders. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13020335<\/a>.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rozensztrauch A, Sebzda A, Smigiel R. Clinical presentation of Rett syndrome in relation to quality of life and family functioning. J Int Med Res. 2021;49(4): 3000605211007714.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lindsay S, Splitt M, Edney S, Berney TP, Knight SJ, Davies KE, O\u2019Brien O, Gale M, Burn J. PPM-X: a new X-linked mental retardation syndrome with psychosis, pyramidal signs, and macroorchidism maps to Xq28. Am J Hum Genet. 1996;58(6):1120\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lambert S, Maystadt I, Boulanger S, Vrielynck P, Destree A, Lederer D, Moortgat S. Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation family with X-linked intellectual disability and spasticity. Eur J Med Genet. 2016;59(10):522\u20135.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cohen D, Lazar G, Couvert P, Desportes V, Lippe D, Mazet P, Heron D. MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry. 2002;159(1):148\u20139.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Savatt JM, Myers SM. Genetic testing in neurodevelopmental disorders. Front Pediatr. 2021;9: 526779.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, Firth HV, Frazier T, Hansen RL, Prock L, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413\u201321.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Gordon-Smith K, Jones LA, Burge SM, Munro CS, Tavadia S, Craddock N. The neuropsychiatric phenotype in Darier disease. Br J Dermatol. 2010;163(3):515\u201322.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Van Den Bossche MJ, Van Wallendael KL, Strazisar M, Sabbe B, Del-Favero J. Co-occurrence of Marfan syndrome and schizophrenia: what can be learned? Eur J Med Genet. 2012;55(4):252\u20135.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mechri A, Mard A, Zaafrane F. Paranoid schizophrenia in a woman with Marfan syndrome. Tunis Med. 2017;95(2):157\u20138.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Romano J, Linares RL. Marfan\u2019s syndrome and schizophrenia: a case report. Arch Gen Psychiatry. 1987;44(2):190\u20132.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019;80(2).<\/p>\n<\/li>\n

  • \n

    Albert U, Bergesio C, Pessina E, Maina G, Bogetto F. Management of treatment resistant obsessive-compulsive disorder. Algorit#hms for pharmacotherapy. Panminerva Med. 2002;44(2):83\u201391.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros-Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, et al. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):716\u201322.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Walkowiak D, Domaradzki J. Are rare diseases overlooked by medical education? Awareness of rare diseases among physicians in Poland: an explanatory study. Orphanet J Rare Dis. 2021;16(1): 400.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Therapies SHG: Rare Disease Impact Report: Insights from patients and the medical community. Shire Human Genetic Therapies, Tech Rep 2013.<\/p>\n<\/li>\n

  • \n

    Sriretnakumar V, Harripaul R, Kennedy JL, So J. When rare meets common: treatable genetic diseases are enriched in the general psychiatric population. Am J Med Genet A. 2024. https:\/\/doi.org\/10.1002\/ajmg.a.63609<\/a>.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lunke S, Bouffler SE, Patel CV, Sandaradura SA, Wilson M, Pinner J, Hunter MF, Barnett CP, Wallis M, Kamien B, et al. Integrated multi-omics for rapid rare disease diagnosis on a national scale. Nat Med. 2023;29(7):1681\u201391.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Thorpe E, Williams T, Shaw C, Chekalin E, Ortega J, Robinson K, Button J, Jones MC, Campo MD, Basel D, et al. The impact of clinical genome sequencing in a global population with suspected rare genetic disease. Am J Hum Genet. 2024;111(7):1271\u201381.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y,…\n","protected":false},"author":2,"featured_media":311280,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[9776,86110,113680,3968,267,3969,4326,20181,218,54920,113682,68277,6448,70,113681,16,15],"class_list":{"0":"post-311279","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-addiction","9":"tag-behavioral-health","10":"tag-diagnostic-delay","11":"tag-general","12":"tag-genetics","13":"tag-human-genetics","14":"tag-medication","15":"tag-medicine-public-health","16":"tag-mental-health","17":"tag-orphan-drug","18":"tag-pharmacology-toxicology","19":"tag-psychiatric","20":"tag-rare-disease","21":"tag-science","22":"tag-treatment-resistant","23":"tag-uk","24":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114957853846290676","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/311279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=311279"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/311279\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/311280"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=311279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=311279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=311279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}